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Abstract
Amiodarone remains the mostly frequently used antiarrhythmic in clinical practice and is
most often used to maintain normal sinus rhythm in patients with atrial fibrillation who
have failed a rate control strategy. Amiodarone has superior efficacy over other
antiarrhythmics, lower risk of torsades de pointes, and a better cardiovascular safety
profile in patients with structural heart disease. However, amiodarone is associated with
notable non-cardiac toxicities affecting the thyroid, lungs, eyes, liver, and central
nervous system. Since 2000, clinicians have been advised to follow amiodarone
monitoring guidelines provided by the Heart Rhythm Society. Adherence to these
recommendations in clinical practice is, however, suboptimal. Pharmacists play a major
role in ensuring the safe and effective use of medications, particularly high-risk
medications such as amiodarone. This qualitative review details the evidence
supporting the role of pharmacist-led amiodarone monitoring services (AMS) in
improving adherence to amiodarone monitoring guidelines and identifying adverse
effects. Five studies were identified and, overall, these programs had a favorable impact
on

improving

adherence

to

guideline-recommended

monitoring

standards

for

amiodarone. The available evidence is limited by the significant variations in study
designs, outcome definitions, lack of patient randomization, and limited generalizability.
Nevertheless, available studies suggest pharmacist-led AMS may improve adherence to
recommended monitoring guidelines and identification of amiodarone-related adverse
effects. Further study is warranted to demonstrate whether or not these services impact
the overall quality of care provided to patients receiving amiodarone, which might justify
broader implementation.
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Introduction
Atrial fibrillation (AF) remains the most frequently observed cardiac arrhythmia in
clinical practice with an estimated prevalence of nearly 6 million in the United States.
Some projections estimate the prevalence of AF will double by 2050.1 Although a rate
control strategy is often preferred, antiarrhythmic medications are indicated in patients
with significant symptoms despite satisfactory rate control.2 Recent trends suggest an
increase in the application of a rhythm control strategy as evident in the rise of AF
ablation procedures, and a 2% per year increase in antiarrhythmic prescriptions.3, 4
Amiodarone is a multi-channel blocker (potassium, sodium, and calcium) and
noncompetitive alpha- and beta-blocker. Although not approved by the Food and Drug
Administration (FDA) for AF, amiodarone remains the most frequently prescribed
antiarrhythmic used for AF, accounting for approximately 45% of all antiarrhythmic
prescriptions.4 This is primarily due to its superior efficacy in maintaining normal sinus
rhythm (NSR) over other antiarrhythmics and demonstrated cardiovascular safety in
patients with structural heart disease.2 However, amiodarone is notoriously associated
with multiple non-cardiac multi-organ toxicities. As such, the Heart Rhythm Society
(formerly the North American Society of Pacing and Electrophysiology) published the
first amiodarone monitoring guidelines in 2000,5 which were most recently updated in
2015.6 These guidelines are summarized in Table 1.
Adherence to amiodarone monitoring guidelines in clinical practice has been
suboptimal. A retrospective cohort study at 10 health maintenance organizations found
that only half of the 1,055 patients on amiodarone received the recommended
monitoring for both liver and thyroid toxicity.7 The available evidence also suggests that
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adherence to baseline monitoring is much higher than follow-up monitoring.8 This is
problematic when the risk of amiodarone-related toxicities increases with longer
duration of use. Furthermore, while a majority of patients receiving amiodarone
experience an adverse effect in the first year of therapy, one-third of these may be
preventable with appropriate long-term monitoring.9
One suggested approach to improving the chronic monitoring of patients
receiving amiodarone therapy has been the utilization of Amiodarone Monitoring
Services (AMS). Considering the role pharmacists play in ensuring the safe and
effective use of medications, it is no surprise that many AMS are pharmacist-led. The
objective of this qualitative review is to summarize the available evidence evaluating the
effectiveness of pharmacist-led AMS in improving adherence to amiodarone monitoring
guidelines and identification of previously unrecognized adverse effects.
Methods
Search Strategy
We conducted a search of English language publications from database
inception through October 30, 2015 using PubMed, CINAHL (EBSCOHost), Web of
Science, Cochrane Library and ProQuest Dissertations & Theses. The search was
divided into three concept groups, including the terminology used to describe
“amiodarone,” “pharmacists,” and “drug monitoring.” Medical Subject Headings (MeSH)
and equivalent controlled vocabulary and keywords were utilized in each database as
appropriate. Additionally, a reference list of the retrieved publications was searched to
identify publications not identified in the database search. The search results and
process of screening and study selection is illustrated in Figure 1.
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Studies were included if they described an AMS that included pharmacists and
reported outcomes that included adherence to amiodarone monitoring guidelines and/or
incidence of patients that experienced a previously unrecognized amiodarone-related
adverse event. Published studies of multidisciplinary models were included if the role of
the pharmacist was clearly described and a primary component of the intervention. For
purposes of this review, pre-post studies were considered acceptable. Broad drug
monitoring programs that did not focus on amiodarone were excluded. Abstracts, letters
to the editor, and editorials were also excluded from this review.
Results
Two investigators (DD, MK) independently identified five articles that met our
inclusion criteria. A summary of included studies is listed in Table 2. Study sites
included outpatient clinics at an academic medical center,10 integrated healthcare
systems,11-13 and a private, university-affiliated cardiology clinic.14 The respective study
designs included three unmatched retrospective cohort studies11-13 and two uncontrolled
pre-post studies.10,14 Adherence to amiodarone monitoring guidelines was a primary
clinical outcome for all of the studies,10-14 while the reporting of amiodarone-related
adverse effects was reported in all but one study.15
Study methods included physician-pharmacist protocols or algorithms,11,14
electronic tracking tools,13 and face-to-face outpatient clinic visits.10,11,14 Pharmacists’
primary role in each study involved ensuring monitoring parameters were obtained or
scheduled. Additional interventions included recommending antiarrhythmic dose
adjustments, identifying and making recommendations for managing drug-drug
interactions and/or adverse drug reactions, obtaining medication histories, and providing
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patient education. Several of the monitoring programs were interdisciplinary
collaborative-care models that included other healthcare professionals, such as
electrophysiologists,10

general

cardiologists,13,14

and

registered

nurses,14

but

pharmacists served in a primary role in each of these.
Evaluation of Clinical Outcomes
Retrospective Cohort Studies
Three studies evaluated adherence to amiodarone monitoring guidelines by
comparing patients followed by an AMS to a retrospective cohort of patients that did not
participate in the AMS (i.e., usual care). The study follow-up period after implementation
of the AMS was 12 months for each of these studies. Overall, patients followed by the
AMS had significantly higher rates of adherence to the recommended amiodarone
monitoring guidelines compared to usual care. Adherence to the recommended
baseline monitoring parameters varied between studies, but generally occurred in less
than 50% of the patients.11-13
Graham et al11 reported no difference between groups at baseline, except for
eye exams, which occurred more frequently in the intervention group. Johnson et al13
observed adherence to baseline monitoring of alanine transaminase (ALT) and
electrocardiogram (ECG) was significantly higher in the intervention group compared to
usual care. Spence et al.12 reported baseline monitoring of ALT, thyroid stimulating
hormone (TSH), pulmonary function tests (PFT), and chest x-ray occurred more
frequently in the intervention group. All three studies reported significantly higher
adherence to follow-up liver function test (LFT) monitoring in the intervention group
compared to usual care, although the recommended monitoring of LFT in the study by
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Graham et al10 occurred twice as frequently as the studies by Johnson et al.13
Incidence of identified adverse events was reported in two studies.11,13 Graham
et al.11 reported 17% of patients in the AMS group had a documented TSH elevation,
compared to 10% of patients in the control group (p=0.23). Thyroid abnormalities were
also the most common adverse event reported by Johnson et al,13 but the overall rate of
confirmed amiodarone-related adverse events was significantly lower in patients
followed by the AMS (5.4% vs. 9.3%; p=0.031).
Longitudinal Studies
Two studies10,14 analyzed the effectiveness of the AMS using a pre/postintervention study design. Sanoski et al9 reported that recommended laboratory
monitoring occurred in only 23% of patients before referral to the AMS. Before enrolling
in the AMS, the patients were followed by their primary physician for a mean of 16.3 +
25.5 months. After a mean follow-up of 9.2 + 5.5 months in the AMS, 90% of patients
received recommended laboratory monitoring (p<0.001). Overall adherence rates to
amiodarone monitoring parameters were not reported by Tafreshi et al,14 but the study
did report an increase in PFT monitoring from only 5% at baseline to 77.5% after
referral to the AMS.
Previously unrecognized adverse effects were identified, post-referral to the
AMS, in 35% and 19% of patients in the studies by and Sanoski et al10 and Tafreshi et
al,14 respectively. The most commonly detected adverse effects in both studies were
thyroid-related and pulmonary toxicities. Unrecognized thyroid abnormalities were
reported in 13% of patients by Sanoski et al10 and 9% of patients by Tafreshi et al.14
Pulmonary fibrosis was diagnosed in 6.7% of the patients followed by the AMS in the
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study by Sanoski et al.10 Unspecified pulmonary toxicity was recognized in 9.1% of the
patients in the Tafreshi et al study.14
Discussion
An extensive search of available literature revealed five studies that evaluated
the impact of pharmacist-led AMS on adherence to amiodarone monitoring guidelines,
and identification of previously unrecognized adverse effects. The available evidence
favors the use of pharmacist-led AMS to ensure patients receiving chronic amiodarone
therapy are appropriately monitored. Greater involvement of pharmacists in the
monitoring of patients receiving long-term amiodarone therapy could improve the safe
use of this high-risk medication.
Interestingly, our review found that thyroid abnormalities and pulmonary toxicity
were the most commonly observed amiodarone-related toxicities. Thyroid function
abnormalities are common with amiodarone and of concern given the known effects
these abnormalities have on cardiac contractility and output, blood pressure, and
arrhythmia pathogenesis.15 One study found a 60% increased risk of mortality in heart
failure patients with an ejection fraction <35% and baseline or new-onset abnormal
thyroid function during the study follow-up period.16 Unsurprisingly, new onset thyroid
abnormalities were nearly four times more common in patients receiving amiodarone.16
These data highlight the importance of thyroid function monitoring in patients receiving
amiodarone as early identification and treatment may prevent fatal adverse sequelae in
patients with cardiovascular disease.
While one of the studies included in our review10 specifically reported the rates of
pulmonary fibrosis, others were more vague and simply reported rates of general
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pulmonary toxicity. This is important considering amiodarone-induced pulmonary toxicity
can manifest itself in various ways with the most serious being pulmonary fibrosis
associated with acute respiratory distress syndrome.17 While the mortality rate of
amiodarone-induced pulmonary fibrosis has been reported to be as high as 10%, an
early diagnosis may improve survival in these patients.5 Thus, a high clinical suspicion
in a patient with unexplained dyspnea should warrant immediate evaluation. Appropriate
follow-up may help identify those with possible pulmonary toxicity before the
development of irreversible pulmonary fibrosis.
As demonstrated in this study, current amiodarone monitoring practices remain
suboptimal, potentially due to the fractured care across general and specialty
caregivers. Team-based models of care including pharmacists, have been shown to
improve cardiovascular clinical outcomes,18 reduce preventable adverse effects,19 and
readmission rates.20 Despite the potential benefit of such collaborative practice models,
broader inclusion of pharmacists in medical practices is limited by lack of a formalized
reimbursement structure.21 The case could be made that ensuring proper monitoring of
amiodarone, and possibly other antiarrhythmics, may have a favorable impact on
reducing healthcare costs. A rhythm control approach costs approximately $5,000 more
per person than rate control and has been linked to a higher rate of hospitalizations.22
The advent of efforts to restructure payment models based on quality of care in the
private sector may provide financial justification for broader implementation of
pharmacist-led AMS. Ultimately, the economical feasibility of AMS is beyond the scope
of this review and warrants further study.
The following limitations should be considered when interpreting the findings of
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this qualitative review. We found significant variations in study designs and outcome
definitions, and none of the studies randomized patients. The retrospective nature of
these studies does not rule out the possibility of missing data and inability to capture
data outside of integrated health care systems to confound these findings. For these
reasons, it was not feasible to combine results and perform a meta-analysis.
Additionally, the available amiodarone monitoring guidelines are not evidence-based, in
the sense that no studies have tested whether prospective monitoring actually prevents
amiodarone-related adverse effects. With that said, a notable number of patients in
these studies required dose adjustments, therapy discontinuation, and had previously
unrecognized and new onset adverse effects due to amiodarone. This suggests that
prospective monitoring may be an effective means to mitigate the adverse effects
associated with amiodarone.
Conclusion
To our knowledge, this is the first compilation of available studies evaluating the
effectiveness of pharmacist-led AMS. Our review of the literature identified five studies
of pharmacist-led AMS to improve amiodarone monitoring and identify potential
amiodarone-related adverse effects. This preliminary evidence suggests these
programs can improve adherence to amiodarone monitoring guidelines and recognition
of amiodarone-related adverse effects. However, the study quality was generally poor
and we found no prospective, randomized studies. A national shift toward quality-based
payment models may justify further consideration of pharmacist-led AMS to monitor
patients receiving chronic amiodarone therapy, but additional studies are warranted.

11
Systematic Review of Amiodarone Monitoring Services

References
1. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015
update: a report from the American Heart Association. Circulation 2015;131(4):e29322.
2. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the
management of patients with atrial fibrillation: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines and the
Heart Rhythm Society. J Am Coll Cardiol 2014;64(21):2246-2280.
3. Martin-Doyle W, Essebag V, Zimetbaum P, Reynolds MR. Trends in US
hospitalization rates and rhythm control therapies following publication of the
AFFIRM and RACE trials. J Cardiovasc Electrophysiol 2011;22:548-553.
4. IMF Health. National prescription auditTM: 2006-2010. (Extracted January 2011).
5. Goldschlager N, Epstein AE, Naccareli G, Olshansky B, Singh B. Practical
guidelines for clinicians who treat patients with amiodarone. Arch Intern Med
2000;160:1741-1748.
6. Epstein AE, Olshansky B, Naccarelli GV, et al. Practical management guide for
clinicians who treat patients with amiodarone. Am J Med 2015; doi:
10.1016/j.amjmed.2015.08.039.
7. Raebel MA, Carroll NM, Simon SR, et al. Liver and thyroid monitoring in ambulatory
patients prescribed amiodarone in 10 HMOs. J Manag Care Pharm 2006;12:656664.
8. Bickford CL, Spencer AP. Adherence to the NASPE guideline for amiodarone
monitoring at a medical university. J Manag Care Pharm 2006;12:254–259.
9. Stelfox HT, Ahmed SB, Fiskio J, Bates DW. Monitoring amiodarone's toxicities:
eecommendations, evidence, and clinical practice. Clin Pharmacol Ther
2004;75:110-22.
10. Sanoski CA, Schoen MD, Gonzalez RC, Avitall B, Bauman JL. Rationale,
development, and clinical outcomes of a multidisciplinary amiodarone clinic.
Pharmacotherapy 1998;18;(6 Pt 2):146S–151S.
11. Graham MR, Wright MA, Manley HJ. Effectiveness of an amiodarone protocol and
management clinic in improving adherence to amiodarone monitoring guidelines. J
Pharm Technol 2004;20:5–10.

12
Systematic Review of Amiodarone Monitoring Services

12. Spence MM, Polzin JK, Weisberger CL, Martin JP, Rho JP, Willick GH: Evaluation of
a pharmacist-managed amiodarone monitoring program. J Manag Care Pharm
2011;17:513–522.
13. Johnson SG, Canty K, Billups S, Schimmer J. Adherence to amiodarone monitoring
recommendations before and after implementation of a centralized pharmacy
service: A Cohort Study. J Pharm Pract 2010; 23:536–539.
14. Tafreshi J, Chui MA, Riley AB. Implementation of an amiodarone ambulatory care
clinic. Am J Health-Syst Pharm 2009; 66:1997–2001.
15. Klein I, Danzi S. Thyroid disease and the heart. Circulation 2007;116:1725-1735.
16. Mitchell JE, Hellkamp AS, Mark DB, et al. Thyroid function in heart failure and
impact on mortality. JACC Heart Fail 2013;1(1):48-55.
17. Wolkove N, Baltzan M. Amiodarone pulmonary toxicity. Can Respir J 2009;16(2):4348.
18. Gattis WA, Hasselblad V, Whellan DJ, O'Connor CM. Reduction in heart failure
events by the addition of a clinical pharmacist to the heart failure management team:
Results of the pharmacist in heart failure assessment recommendation and
monitoring (PHARM) study. Arch Intern Med 1999;159(16):1939–1945.
19. Kucukarslan SN, Peters M, Mlynarek M, Nafziger DA. Pharmacists on rounding
teams reduce preventable adverse drug events in hospital general medicine units.
Arch Intern Med 2003;163(17):2014–2018.
20. Cavanaugh JJ, Jones CD, Embree G, et al. Implementation Science Workshop:
Primary Care-Based Multidisciplinary Readmission Prevention Program. J Gen
Intern Med 2014;29:798–804.
21. Dunn SP, Birtche KK, Beavers CJ, et al. The role of the clinical pharmacist in the
care of patients with cardiovascular disease. J Am Coll Cardiol 2015;66:2129-39.
22. Marshall D, Levy AR, Vidaillet H, et al; AFFIRM and CORE investigators. Costeffectiveness of rhythm versus rate control in atrial fibrillation. Ann Intern Med.
2004;141:653-661

